Gilgamesh Pharma Inc.
About
Issuer
- Entity type
- Corporation
- Jurisdiction
- Delaware
- Sector
- Other
- Headquarters
- New York, NY
- Street
- 113 University Place, Suite 1019
- Zip
- 10003
Offering
- Total offering
- $60M
- Amount sold
- $60M
- First sale
- Mar 9, 2026
- Min investment
- $50k
- Securities
- Equity, Other
- Federal exemption
- Rule 506(b)
- Investors so far
- 40
How this filing compares
Ranked #18 of 222 Other filings in March 2026 by offering amount.
Median Other filing in March 2026: $5.4M. This offering is 11.1× the median.
Other New York filings this week: AIM Investors Employee LP, AIM Investors Employee Offshore LP, ASports Private Investors, LLC, Averill Partners, LP, Banyan Tree Capital Partners, L.P.
Leadership
Jonathan Sporn — Executive Officer (also: Director)
Andrew Kruegel — Executive Officer (also: Director)
Zia Huque — Director
Amy Kruse — Director
Robert Berman — Director
Phil Skolnick — Director
Filing details
Gilgamesh Pharma Inc. filed a Form D with the SEC on March 24, 2026.